



Aurobindo Pharma receives Swissmedic approvals for Amlodipine Besylate Tablets and Metformin Hydrochloride Tablets

Aurobindo Pharma Limited is pleased to announce that it has received two approvals from Swissmedic, Government of Switzerland for the license of Amlodipine APL 5mg and 10mg tablets and Metformin APL 500mg, 850mg and 1000mg tablets

Amlodipine APL 5mg and 10mg tablets falls under the Cardio Vascular Disorder (CVD) therapeutic segment and is indicated for the treatment of angina pectoris and of mild to moderate hypertension, alone or in combination with other antihypertensives.

Metformin APL 500mg, 850mg and 1000mg tablets is a biguanide antidiabetic and indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.

Aurobindo now has four products approvals from Swissmedic.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com